Immunotherapy for paediatric diffuse large B-cell lymphoma: A review of current clinical trials and future directions

EJC paediatric oncology Pub Date : 2025-03-28 DOI:10.1016/j.ejcped.2025.100228

Anne van Kuijk , Pamela Kearns , G.A. Amos Burke

{"title":"Immunotherapy for paediatric diffuse large B-cell lymphoma: A review of current clinical trials and future directions","authors":"Anne van Kuijk , Pamela Kearns , G.A. Amos Burke","doi":"10.1016/j.ejcped.2025.100228","DOIUrl":null,"url":null,"abstract":"<div><div>Paediatric diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive form of non-Hodgkin lymphoma. Although rituximab has significantly improved outcomes in both adult and paediatric patients, challenges remain for those who relapse or are resistant to the initial treatment. This review examines recent clinical trials investigating various immunotherapies for relapsed or refractory (R/R) paediatric DLBCL, including immunomodulatory agents, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, checkpoint inhibitors, and chimeric antigen receptor (CAR) T-cell therapy. A comprehensive search identified forty-eight relevant trials with significant focus on CAR-T cell therapy. This review highlights the potential benefits of these novel therapies for improving the survival rate and quality of life of paediatric patients. However, it also underscores the need for increased international collaboration and paediatric-specific research to address the unique challenges in treating this vulnerable population. Future directions include the integration of personalised medicine and development of chemotherapy-free regimens.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100228"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJC paediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772610X25000157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Paediatric diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive form of non-Hodgkin lymphoma. Although rituximab has significantly improved outcomes in both adult and paediatric patients, challenges remain for those who relapse or are resistant to the initial treatment. This review examines recent clinical trials investigating various immunotherapies for relapsed or refractory (R/R) paediatric DLBCL, including immunomodulatory agents, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, checkpoint inhibitors, and chimeric antigen receptor (CAR) T-cell therapy. A comprehensive search identified forty-eight relevant trials with significant focus on CAR-T cell therapy. This review highlights the potential benefits of these novel therapies for improving the survival rate and quality of life of paediatric patients. However, it also underscores the need for increased international collaboration and paediatric-specific research to address the unique challenges in treating this vulnerable population. Future directions include the integration of personalised medicine and development of chemotherapy-free regimens.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

儿童弥漫性大b细胞淋巴瘤的免疫治疗：当前临床试验的回顾和未来的方向

小儿弥漫性大b细胞淋巴瘤（DLBCL）是一种罕见但侵袭性的非霍奇金淋巴瘤。尽管利妥昔单抗显著改善了成人和儿科患者的预后，但对于那些复发或对初始治疗有耐药性的患者来说，挑战仍然存在。本文综述了最近的临床试验，研究了复发或难治性（R/R）儿科DLBCL的各种免疫疗法，包括免疫调节剂、单克隆抗体、抗体-药物偶联物、双特异性抗体、检查点抑制剂和嵌合抗原受体（CAR） t细胞疗法。一项全面的搜索确定了48项相关试验，重点关注CAR-T细胞疗法。这篇综述强调了这些新疗法在提高儿科患者生存率和生活质量方面的潜在益处。然而，它也强调需要加强国际合作和针对儿科的研究，以应对治疗这一弱势群体的独特挑战。未来的发展方向包括个性化医疗的整合和无化疗方案的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

EJC paediatric oncology

CiteScore

0.20

自引率

0.00%

发文量